[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Laboratorios Silanes S.A. de C.V.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":122},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,73,97],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100586554","phase-3-confirmatory-study-on-the-efficacy-and-safety-of-the-fixed-dose-combination-of-desloratadinebetamethasone-versus-desloratadine-100586554",false,"NCT06916884","Confirmatory Study on the Efficacy and Safety of the Fixed-dose Combination of Desloratadine\u002FBetamethasone Versus Desloratadine","Confirmatory Study on the Efficacy and Safety of the Fixed-dose Combination of Desloratadine\u002FBetamethasone Versus Desloratadine as Treatment in Patients With Allergic Rhinitis","DESCUBRA","Inclusion Criteria:\n\n* Willing to participate in the study and able to provide written informed consent.\n* Clinical diagnosis (based on medical history and physical examination) of active allergic rhinitis at study entry.\n* Patients presenting with moderate to severe nasal symptoms, with a Total Nasal Symptom Score (TNSS) ≥5.\n* In the case of women of childbearing potential who are sexually active, the use of an acceptable contraceptive method (barrier and\u002For hormonal), as determined by the investigator.\n* In the opinion of the Principal Investigator or treating physician, the patient is indicated for treatment with the investigational product and may derive clinical benefit from it.\n\nExclusion Criteria:\n\n* Patients for whom the investigational drug is medically contraindicated.\n* Known allergy or hypersensitivity to the active ingredient, study medications, related products, or excipients.\n* History of nasal trauma (surgical or accidental) within the past week.\n* Positive pregnancy test, pregnant or breastfeeding women, or women planning to become pregnant during the course of the study.\n* Acute or chronic lower or upper respiratory tract infections, such as the common cold, influenza, pneumonia, bronchitis, or chronic sinusitis.\n* History of non-allergic rhinitis, such as chronic non-allergic rhinitis, drug-induced rhinitis, atrophic rhinitis, hormonal rhinitis, or unilateral rhinitis, as reported in the medical history or patient interview.\n* History of nasal polyposis, primary ciliary dyskinesia syndrome, and\u002For non-allergic rhinitis with eosinophilia syndrome (NARES).\n* Current smokers, or history of alcohol and\u002For drug abuse in the past year according to DSM-V criteria.\n* History of seizure disorders, status epilepticus, or generalized tonic-clonic seizures.\n* History of chronic hepatic failure classified as Child-Pugh C, as reported in the medical history or patient interview.\n* History of chronic renal failure (glomerular filtration rate \\\u003C 30 mL\u002Fmin\u002F1.73 m²), as reported in the medical history or patient interview.\n* Any condition, in the investigator's opinion, that affects prognosis or precludes outpatient management, which must be evaluated by the principal investigator to determine the subject's eligibility.\n* History of severe, progressive, unstable, or advanced disease of any kind that could interfere with efficacy and safety evaluations or pose a risk to the patient.\n* Oncology patients (except those with basal cell skin cancer) or patients with serious illnesses who, in the investigator's opinion, have a poor prognosis or life expectancy of less than one year, including those with mental health disorders.\n* Active participation in another clinical trial involving an investigational treatment or participation in any clinical study within the previous two weeks.\n* Patients whose participation in the study may be influenced (e.g., employees of the research center or sponsor, incarcerated individuals, etc.).\n* Patients with symptoms suggestive of active COVID-19 infection (e.g., fever, cough, dyspnea) and\u002For contact within the past 14 days with a suspected or confirmed COVID-19 case and\u002For a positive COVID-19 test.","ALL","18 Years","60 Years",{"count":21,"type":22},70,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","Phase IIIb , longitudinal, multicenter, randomized, double-blind, to evaluate efficacy and safety of the fixed-dose combination of Desloratadine 5 mg \u002F Betamethasone 0.25 mg versus Desloratadine 5 mg monotherapy as treatment for symptoms associated with allergic rhinitis.",[28],"Allergic Rhinitis",[30,31,32],"rhinitis","allergies","respiratory system","RECRUITING","2025-04-01",{"date":36,"type":37},"2025-04-08","ACTUAL",{"date":39,"type":37},"2024-11-11",{"date":41,"type":22},"2025-06-11",{"name":43,"class":44},"Laboratorios Silanes S.A. de C.V.","INDUSTRY",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":45},"100582463","phase-3-efficacy-and-safety-of-celecoxibacetaminophen-versus-celecoxib-for-diagnosed-osteoarthritis-in-acute-exacerbation-100582463","NCT06863636","Efficacy and Safety of Celecoxib\u002FAcetaminophen Versus Celecoxib for Diagnosed Osteoarthritis in Acute Exacerbation","Efficacy and Safety Study of the Fixed-dose Combination of Celecoxib\u002FAcetaminophen Compared to Celecoxib for the Treatment of Pain in Patients Diagnosed With Osteoarthritis in Acute Exacerbation","PRECEDENT","Inclusion Criteria:\n\n* Voluntarily agrees to participate in the study and provides written informed consent.\n* Prior diagnosis of knee or hip osteoarthritis based on clinical criteria (according to the American College of Rheumatology (ACR) criteria described in Annex 5).\n* Pain in the affected joint with exacerbation lasting no more than 3 weeks.\n* Patient reports moderate to severe pain intensity (VAS ≥ 40 mm).\n* For women of childbearing potential (a woman is considered fertile after menarche and until postmenopause unless permanently sterile), they must agree to use at least ONE of the following contraceptive methods during the study:\n\nBarrier methods: diaphragm, cervical cap, male condom, female condom, spermicide foam, sponge, or film.\n\nHormonal methods: combined oral contraceptives, injectable contraceptives, subdermal implant, contraceptive patch.\n\nIntrauterine device (IUD): copper or silver IUD, Levonorgestrel intrauterine system (IUS), and\u002For combinations of the above as deemed acceptable by the physician.\n\nWomen are considered not of childbearing potential if they meet at least ONE of the following criteria:\n\nPostmenopausal. Premenopausal woman with at least ONE of the following: hysterectomy, bilateral salpingectomy, or bilateral oophorectomy.\n\nMale subjects must agree to use a male condom as a contraceptive method during the study.\n\n* At the discretion of the Principal Investigator (PI) or treating physician, the subject has an indication for treatment with the investigational product and may derive clinical benefit from it.\n\nExclusion Criteria:\n\n* Intolerance or allergy to the investigational product or any of its components (as reported in the medical history and patient interview).\n* Participation in another clinical study involving an investigational treatment or participation in one within the last two weeks prior to the study start.\n* Potential study bias due to employment or relationship with the research center, sponsor, or being part of a vulnerable population.\n* Medical conditions affecting prognosis that prevent outpatient management, to be evaluated by the Principal Investigator for subject inclusion relevance.\n* History of advanced, severe, progressive, or unstable disease of any kind that may interfere with efficacy and safety assessments or pose a special risk to the patient.\n* Medical contraindication to the investigational product.\n* History of allergic reaction to NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), Acetaminophen, or known hypersensitivity to any formulation components.\n* Significant gastrointestinal disorders, such as gastric ulcers, Crohn's disease, ulcerative colitis, or gastrointestinal bleeding.\n* Prior opioid treatment within the last five days, as reported in the medical history.\n* History of treatment failure with COX-2 selective inhibitors, as documented in the medical history.\n* History of chronic somatic pain unrelated to knee or hip osteoarthritis (e.g., fibromyalgia, metastatic disease, or Paget's disease).\n* History of alcohol or drug abuse within the past year.\n* Current treatment with NSAIDs, including COX-2 inhibitors, within the last 72 hours before signing informed consent (except for aspirin used for cardioprotective purposes).\n* History of arthroscopy, viscosupplementation, or intra-articular steroid use in the last three months.\n* Previous surgery on the affected joint within the last six months.\n* Major trauma in the affected joint within the last three weeks.\n* History of chronic liver failure (Child-Pugh A, B, or C).\n* History of acute or severe renal failure (glomerular filtration rate \\\u003C30 ml\u002Fmin\u002F1.73 m²), as reported in the medical history.\n* Significant coagulation disorders (e.g., Von Willebrand disease, hemophilia, vitamin K deficiency) or current use of anticoagulants.\n\nOncologic patients (except basal cell carcinoma) or those with severe illnesses that, according to the investigator, have a poor prognosis or a life expectancy of less than one year, including severe mental illness.\n\n* Patients with symptoms suggestive of active COVID-19 infection (e.g., fever, cough, dyspnea) and\u002For contact within the last 14 days with a suspected or confirmed COVID-19 patient.\n* Positive pregnancy test, pregnant women, those currently breastfeeding, or those planning pregnancy during the study period.","40 Years",{"count":56,"type":22},231,[25],"This is a Phase III, longitudinal, multicenter, randomized, double-blind clinical trial designed to evaluate the efficacy and safety of a fixed-dose combination of celecoxib and acetaminophen compared to celecoxib monotherapy for the treatment of pain associated with acute exacerbations of osteoarthritis.",[60,61,62],"Joint Pain","Knee Osteoarthritis","Hip Osteoarthritis",[64,61,62,65],"Joint pain","Acute pain",{"date":67,"type":37},"2025-04-04",{"date":69,"type":37},"2024-09-09",{"date":71,"type":22},"2025-11-30",{"name":43,"class":44},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":45},"100582468","phase-3-efficacy-anda-safety-of-etoricoxib-with-betamethasone-for-the-treatment-of-acute-gout-arthritis-100582468","NCT06863701","Efficacy Anda Safety of Etoricoxib With Betamethasone for the Treatment of Acute Gout Arthritis","Efficacy and Safety Study for the Combination of Etoricoxib \u002F Betamethasone Compared to Etoricoxib for the Treatment of Patients Diagnosed With Acute Gout Arthritis","Inclusion Criteria:\n\n* Willing to participate in the study and provide written informed consent.\n* Women of childbearing potential and sexually active must use an acceptable contraceptive method (barrier and\u002For hormonal) as determined by the investigator.\n* History of hyperuricemia diagnosis (uric acid \\> 7 mg\u002FdL) reported in medical history or patient interview.\n* Clinical diagnosis of acute gouty arthritis with a score of at least 4 based on the following criteria: Male (2 points), history of a similar episode (2 points), symptom onset within the last 24 hours (0.5 points), joint redness (1 point), involvement of the first metatarsophalangeal joint (2.5 points), and hypertension or at least one cardiovascular disease (1.5 points).\n* Acute episode characterized by severe pain, inflammation, edema, and erythema in the affected joint (≤ 48 hours before study inclusion).\n* In the opinion of the Principal Investigator or treating physician, the patient is eligible for treatment with the investigational product and may benefit clinically\n\nExclusion Criteria:\n\n* Patients participating in another clinical study involving an investigational treatment or participation in one within the two weeks prior to study initiation.\n* Patients whose participation in the study may be influenced (e.g., employment relationship with the research center or sponsor, vulnerable populations, etc.).\n* In the investigator's judgment, any condition that affects prognosis and prevents outpatient management, which must be assessed by the principal investigator to determine the patient's eligibility.\n* History of severe, progressive, or unstable advanced disease of any kind that may interfere with efficacy and safety evaluations or put the patient at risk.\n* Pregnant or breastfeeding patients.\n* The study medication is contraindicated for medical reasons.\n* History of intolerance or allergic reaction to NSAIDs (nonsteroidal anti-inflammatory drugs), paracetamol, or known hypersensitivity to any component of the formulation.\n* Significant history of gastrointestinal disorders (e.g., gastric ulcer, Crohn's disease, ulcerative colitis, gastrointestinal bleeding, etc.).\n* History of congestive heart failure (NYHA classification II-IV), established ischemic heart disease, peripheral arterial disease, and\u002For cerebrovascular disease (including patients who have recently undergone coronary revascularization or angioplasty).\n* Treatment with systemic corticosteroids for the management of acute gouty arthritis within two weeks before study initiation.\n* Treatment with NSAIDs within 48 hours prior to study initiation, except for aspirin at cardioprotective doses.\n* History of treatment failure with selective COX-2 inhibitors, as reported in medical history or patient interview.\n* Presence of acute polyarticular gout affecting more than four joints.\n* History of alcohol or drug abuse within the past year.\n* Clinical suspicion of joint infection or another joint disease different from acute gouty arthritis.\n* History of chronic liver failure (Child-Pugh A, B, and\u002For C), as reported in medical history or patient interview.\n* History of chronic renal failure (glomerular filtration rate \\\u003C30 ml\u002Fmin\u002F1.73 m²), as reported in medical history or patient interview.\n* Significant history of known coagulation disorders (e.g., Von Willebrand disease, hemophilia, vitamin K deficiency, etc.) or use of anticoagulants, as reported in medical history or patient interview.\n* Oncology patients (except for basal cell skin cancer) or patients with severe diseases that, in the investigator's opinion, have a severe prognosis or a life expectancy of less than one year, as well as patients with mental illnesses.\n* Patients with symptoms suggestive of active COVID-19 infection (e.g., fever, cough, shortness of breath) and\u002For contact within the last 14 days with a suspected or confirmed COVID-19 case.",{"count":81,"type":22},72,[25],"Phase III longitudinal, multicenter, randomized, double-blind clinical trial. The aim of this study is to evaluate the efficacy and safety of the Fixed-Dose Combination of Etoricoxib\u002FBetamethasone Versus Etoricoxib in Patients With Acute Gouty Arthritis",[85,86],"Gout Arthritis","Gout Attack",[85,86,88,89],"Etoricoxib","Betamethasone",{"date":91,"type":37},"2025-04-03",{"date":93,"type":37},"2025-01-27",{"date":95,"type":22},"2027-01-31",{"name":43,"class":44},{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":23,"phases":106,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":45},"100556945","phase-3-efficacy-and-safety-in-the-combination-of-ibuprofen--loratadine-versus-ibuprofen-versus-loratadine-100556945","NCT06531707","Efficacy and Safety in the Combination of Ibuprofen \u002F Loratadine Versus Ibuprofen Versus Loratadine","Efficacy and Safety of Ibuprofen\u002FLoratadine Fixed-dose Combination Versus the Fixed-dose Administration of Monotherapy as Symptomatic Treatment for Patients With the Common Cold","Inclusion Criteria:\n\n* Agree to participate in the study and give written informed consent\n* At least 6 points on the Jackson scale according to physical examination and questioning (sneezing, runny nose, nasal obstruction, sore throat, cough, headache, malaise, and chills).\n* Symptoms associated with the common cold with maximum of 3 days since presentation\n* Women of childbearing potential under a medically acceptable method of contraception\n* At the discretion of the Principal Investigator (PI) or treating physician, treatment with the researching product is indicated and may present clinical benefit\n\nExclusion Criteria:\n\n* Patients in whom respiratory symptoms are suspected to be of bacterial origin and generate a clinical picture compatible with: Rhinosinusitis (muco-purulent discharge, headache or facial pain, etc.), lower respiratory tract disease (wheezing, crackles, productive cough, etc.), acute otitis media (otalgia, purulent discharge from the ear, auditory discomfort, etc.).\n* Patients participating in another clinical trial involving an investigational treatment or participation in one within 4 weeks prior to study start\n* Patients in whom participation in the study may be influenced (employment relationship with the research site or sponsor, inmates, etc.)\n* At medical discretion, a disease that affects prognosis and prevents outpatient management, for example, but not limited to: end-stage cancer, kidney, heart, respiratory or liver failure, mental illness or with scheduled surgical or hospital procedures\n* History\u002Fpresence of any disease or condition that, in the opinion of the Investigator, could pose a risk for the patient or confusing the efficacy and safety of the investigational product\n* Patients in whom the study drug is contraindicated for medical reasons\n* Patients with allergy or hypersensitivity to the active substance of the study drugs, related products or excipients (Ibuprofen of Loratadine)\n* Pregnant women, women breastfeeding or planning a pregnancy during the conducting the study\n* Significant history of gastrointestinal diseases (e.g., gastric ulcer, Crohn's disease, Ulcerative Colitis, etc.)\n* History of chronic liver failure Child-Pugh A, B, and\u002For C\n* History of acute renal failure (glomerular filtration rate \\\u003C30 ml\u002Fmin\u002F1.72 m2)\n* Patients with a history of alcohol or drug abuse in the last year\n* Patients with symptoms suggestive of COVID-19 infection (fever, cough, dyspnea) and\u002For contact in the last 14 days with a suspected or positive patient for COVID-19",{"count":105,"type":22},177,[25],"Phase III longitudinal, multicenter, randomized, double-blind clinical trial. The aim of this study is to evaluate the efficacy and safety of the drug combination of Ibuprofen\u002FLoratadine versus Ibuprofen versus Loratadine as monotherapy for the symptomatic treatment of the common cold.",[109],"Common Cold",[109,111,112,113],"Flu","Ibuprofen","Loratadine","2024-07-31",{"date":116,"type":37},"2024-08-02",{"date":118,"type":37},"2024-05-20",{"date":120,"type":22},"2025-02-20",{"name":43,"class":44},""]